IPON

Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office

Retrieved on: 
Wednesday, March 27, 2024
Research, Social anxiety, Composition, Brain, NCE, IPON, Environment, Patent, Incidence, Patient, University, Hyperthermia, Autism spectrum, MDXX, The central science, United States patent law, General Population (album), Test, IP, OTC, Spectrum, MDMA, Intellectual property, FDA, ASD, Food, Pharmaceutical industry

Preclinical testing has shown that the administration of ALA-002 results in significantly lowered incidence of hyperthermia, the major adverse event elicited by racemic generic MDMA.

Key Points: 
  • Preclinical testing has shown that the administration of ALA-002 results in significantly lowered incidence of hyperthermia, the major adverse event elicited by racemic generic MDMA.
  • PharmAla’s patent application included in-vivo experimental animal data, which is generally held to be stronger evidence than computational, or in-silico, modeling.
  • The Company intends to pursue its own clinical research with the novel composition, either alone or with an out-licensing partner.
  • “We are incredibly pleased that USPTO has issued an allowance for the granting of the Composition of Matter patent for ALA-002.

DiagnaMed Strengthening Intellectual Property Support for CERVAI™ Brain Health AI Solution

Retrieved on: 
Thursday, March 14, 2024
Algorithm, IPON, Growth, SME, Intelligence, NRC, Education, Research, IRAP, Software, IP, National Research Council, Intellectual property, Creative industries

The Company has made significant progress in its AI algorithms and software and achieved certain research milestones that merit IP protection for commercializing CERVAI™ Brain Health AI solution.

Key Points: 
  • The Company has made significant progress in its AI algorithms and software and achieved certain research milestones that merit IP protection for commercializing CERVAI™ Brain Health AI solution.
  • Fabio Chianelli, Chairman and CEO of DiagnaMed, commented: “We have made significant technical and operating progress with CERVAI™, our novel brain health AI solution, and we are pleased to strengthen support of our intellectual property for commercialization with a potential $150,000 non-dilutive funding from IPON and IP Assist programs.
  • As part of our global commercialization plans for CERVAI™, we continue to invest in R&D and expand our intellectual property portfolio through patents, copyrights, trademarks and trade secrets.”
    With the IPON Partner Program, DiagnaMed can receive up to $35,000 in initial funding, with a further total grant of $100,000 for intellectual property protection and commercialization services.
  • DiagnaMed has completed IP Assist Level 1 with the IP Assist program and is eligible to receive up to $50,000 for expert IP services.

PharmAla named an Intellectual Property Ontario Client

Retrieved on: 
Thursday, February 22, 2024
MDXX, Research, IPON, ABA, Education, OTC, Work, Drug development, International Society, ACS Chemical Neuroscience, MDMA, University, Intellectual property, IP, Pharmaceutical industry

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) announces today that it has been accepted as a client of Intellectual Property Ontario (IPON).

Key Points: 
  • VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) announces today that it has been accepted as a client of Intellectual Property Ontario (IPON).
  • PharmAla is further pleased to note that IPON has approved its initial Scope of Work pertaining to the national phase entry into numerous markets of the PharmAla ALA and ABA molecule families and will provide a non-dilutive grant of approximately $35,000 to PharmAla to complete this work.
  • “We are pleased to be recognized as a worthy recipient of this grant funding from the Province of Ontario and IPON,” said Dr. Harpreet Kaur, VP of Research at PharmAla Biotech.
  • “As our drug discovery program continues to bear fruit, locking in valuable intellectual property remains a crucial and integral part of PharmAla’s long-term drug discovery program.

FACIT appoints seasoned life science leaders to its Board of Directors

Retrieved on: 
Wednesday, November 1, 2023
Knowledge, Chairperson, IPO, Technology transfer, Ontario Institute for Cancer Research, FACIT, Chan Zuckerberg Biohub, Intellectual property, Research, IPON, Public sector, Science, Cancer, Therapy, Patient, Management

TORONTO, Nov. 1, 2023 /PRNewswire/ - FACIT is pleased to welcome two new directors to its Board, Dr. Maura Campbell and Dr. Laszlo Radvanyi.

Key Points: 
  • TORONTO, Nov. 1, 2023 /PRNewswire/ - FACIT is pleased to welcome two new directors to its Board, Dr. Maura Campbell and Dr. Laszlo Radvanyi.
  • Dr. Campbell also currently serves on the Board of Intellectual Property Ontario (IPON) and was appointed to Ontario's Life Sciences Council (OLSC) along with FACIT President Dr. David O'Neill.
  • FACIT also thanks entrepreneurial scientist Dr. Shana Kelley, for lending her knowledge and leadership as a FACIT director since 2017.
  • "It is a pleasure to welcome Maura and Laszlo to FACIT's expanding Board of Directors", said Mr. John Morrison, FACIT's Board Chair.

Innovative Cancer Immunotherapy Wins 2023 Falcons' Fortunes Pitch Competition

Retrieved on: 
Friday, March 31, 2023
FACIT, Private sector, Intellectual property, Falcon, Culture, IPON, Cancer, Research, Ontario Institute for Cancer Research, IP, Patient, Immunotherapy, Dream, Colorectal cancer, Growth, Therapy, Government, Pharmaceutical industry, Creative industries

TORONTO, March 31, 2023 /PRNewswire/ - FACIT is pleased to announce that the winning pitch for the 10th anniversary Falcons' Fortunes pitch competition and the $100,000 Ernsting Entrepreneurship Award was delivered by Dr. Sumaiyah Rehman, co-founder and CEO of DTPx Therapeutics.

Key Points: 
  • TORONTO, March 31, 2023 /PRNewswire/ - FACIT is pleased to announce that the winning pitch for the 10th anniversary Falcons' Fortunes pitch competition and the $100,000 Ernsting Entrepreneurship Award was delivered by Dr. Sumaiyah Rehman, co-founder and CEO of DTPx Therapeutics.
  • Hosted by commercialization venture group FACIT, the annual competition showcases emerging entrepreneurs and highlights Ontario as a world-leading jurisdiction for cancer research translation.
  • A panel of industry investors selected the best pitch presentation from six Ontario-based entrepreneurs for their cancer innovation.
  • "Fun and spirited events like Falcons' Fortunes are building a culture that will surely make a difference for Ontarians living with cancer."